The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1548
ISSUE 1548
June 4, 2018
Issue 1548
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Diet, Drugs, Devices, and Surgery for Weight Management
June 4, 2018 (Issue: 1548)
Adults with a body mass index (BMI) between 25
and 29.9 kg/m2 are considered overweight. Those
with a BMI ≥30 are considered obese. The initial
recommendation for any weight loss effort is to
achieve a 5-10% reduction in weight, which has...more
- CM Apovian et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015; 100:342.
- AG Tsai and TA Wadden. The evolution of very-low-calorie diets: an update and meta-analysis. Obesity 2006; 14:1283.
- MD Jensen et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 2014; 129:S102.
- FM Sacks et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009; 360:859.
- BC Johnston et al. Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. JAMA 2014; 312:923.
- CD Gardner et al. Effect of low-fat vs low-carbohydrate diet on 12-month weight loss in overweight adults and the association with genotype pattern or insulin secretion: the DIETFITS randomized clinical trial. JAMA 2018; 319:667.
- TM Larsen et al. Diets with high or low protein content and glycemic index for weight-loss maintenance. N Engl J Med 2010; 363:2102.
- VL Webb and TA Wadden. Intensive lifestyle intervention for obesity: principles, practices, and results. Gastroenterology 2017; 152:1752.
- P Little et al. An internet-based intervention with brief nurse support to manage obesity in primary care (POWeR+): a pragmatic, parallel-group, randomised controlled trial. Lancet Diabetes Endocrinol 2016; 4:821.
- AL Ahern et al. Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial. Lancet 2017; 389:2214.
- WC Knowler et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393.
- Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol 2015; 3:866.
- Look AHEAD Research Group et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369:145.
- P Hollander et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013; 36:4022.
- WT Garvey et al. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care 2014; 37:3309.
- Two drugs for weight loss. Med Lett Drugs Ther 2012; 54:69.
- DB Allison et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity 2012; 20:330.
- KM Gadde et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:1341.
- WT Garvey et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012; 95:297.
- SZ Yanovski and JA Yanovski. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014; 311:74.
- KM Gadde et al. Obesity: pathophysiology and management. J Am Coll Cardiol 2018; 71: 69.
- Contrave – a combination of bupropion and naltrexone for weight loss. Med Lett Drugs Ther 2014; 56:112.
- Liraglutide (Victoza) for type 2 diabetes. Med Lett Drugs Ther 2010; 52:25.
- Liraglutide (Saxenda) for weight loss. Med Lett Drugs Ther 2015; 57:89.
- X Pi-Sunyer et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015; 373:11.
- CW le Roux et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 2017; 389:1399.
- Maestro rechargeable system for weight loss. Med Lett Drugs Ther 2016; 58:54.
- MG Sarr et al. The EMPOWER study: randomized, prospective, double-blind, multicenter trial of vagal blockade to induce weight loss in morbid obesity. Obes Surg 2012; 22:1771.
- S Ikramuddin et al. Effect of reversible intermittent intra-abdominal vagal nerve blockade on morbid obesity: the ReCharge randomized clinical trial. JAMA 2014; 312:915.
- AspireAssist - A new device for weight loss. Med Lett Drugs Ther 2016; 58:109.
- CC Thompson et al. Percutaneous gastrostomy device for the treatment of class II and class III obesity: results of a randomized controlled trial. Am J Gastroenterol 2017; 112:447.
- Obalon Balloon System - another gastric balloon for weight loss. Med Lett Drugs Ther 2017; 59:102.
- ReShape and Orbera - two gastric balloon devices for weight loss. Med Lett Drugs Ther 2015; 57:122.
- FDA Update: Potential risks with liquid-filled intragastric balloons – letter to health care providers. Available at: www.fda.gov. Accessed May 24, 2018.
- Z Khorgami et al. Trends in utilization of bariatric surgery, 2010-2014: sleeve gastrectomy dominates. Surg Obes Relat Dis 2017; 13:774.
- PE O'Brien et al. Long-term outcomes after bariatric surgery: fifteen-year follow-up of adjustable gastric banding and a systematic review of the bariatric surgical literature. Ann Surg 2013; 257:87.
- Z Juodeikis and G Brimas. Long-term results after sleeve gastrectomy: a systematic review. Surg Obes Relat Dis 2017; 13:693.
- MT Young et al. Use and outcomes of laparoscopic sleeve gastrectomy vs laparoscopic gastric bypass: analysis of the American College of Surgeons NSQIP. J Am Coll Surg 2015; 220:880.
- JH Mehaffey et al. 10-year outcomes after roux-en-Y gastric bypass. Ann Surg 2016; 264:121.
- TD Adams et al. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med 2017; 377:1143.
- GJ Service et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005; 353:249.
- P Salminen et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic roux-en-y gastric bypass on weight loss at 5 years among patients with morbid obesity: the SLEEVEPASS randomized clinical trial. JAMA 2018; 319:241.
- R Peterli et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic roux-en-y gastric bypass on weight loss in patients with morbid obesity: the SM-BOSS randomized clinical trial. JAMA 2018; 319:255.
- AP Courcoulas et al. Seven-year weight trajectories and health outcomes in the longitudinal assessment of bariatric surgery (LABS) study. JAMA Surg 2017 Dec 6 (epub).
- G Mingrone et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012; 366:1577.
- PR Schauer et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366:1567.
- PR Schauer et al. Bariatric surgery versus intensive medical therapy for diabetes – 5-year outcomes. N Engl J Med 2017; 376:641.
- S Ikramuddin et al. Lifestyle intervention and medical management with vs without roux-en-y gastric bypass and control of hemoglobin A1c, LDL cholesterol, and systolic blood pressure at 5 years in the diabetes surgery study. JAMA 2018; 319:266.
- L Sjöström et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307:56.
- O Reges et al. Association of bariatric surgery using laparoscopic banding, roux-en-y gastric bypass, or laparoscopic sleeve gastrectomy vs usual care obesity management with all-cause mortality. JAMA 2018; 319:279.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1548
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.